Acorda Therapeutics (ACOR) – Company Press Releases
-
Acorda Therapeutics Announces Delisting from Nasdaq
-
Acorda Therapeutics Announces Nasdaq Delisting Notification
-
Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement
-
Acorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024
-
Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024
-
Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025
-
Acorda Therapeutics Reports Third Quarter 2023 Financial Results
-
Acorda Third Quarter 2023 Update: Webcast/Conference Call Scheduled for November 13, 2023
-
Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®
-
Acorda Therapeutics Reports Second Quarter 2023 Financial Results
-
Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: “For The Fighters™”
-
Acorda Second Quarter 2023 Update: Webcast/Conference Call Scheduled for August 8, 2023
-
Tom Burns Elected to the Acorda Therapeutics Board of Directors
-
Acorda Therapeutics Regains Compliance with Nadaq Minimum Bid Price Requirement
-
Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split
-
Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split
-
Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A
-
Acorda Therapeutics Reports First Quarter 2023 Financial Results
-
Acorda Therapeutics to Make June 2023 $6.2 Million Interest Payment on Secured Debt in Cash
-
Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China
-
Acorda First Quarter 2023 Update: Webcast/Conference Call Scheduled for May 11, 2023
-
Acorda Therapeutics to Present INBRIJA® Data at the American Academy of Neurology Annual Meeting
-
Acorda Launches INBRIJA® TV Commercial for Parkinson’s Awareness Month
-
Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A
-
Acorda Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
-
ESTEVE Launches INBRIJA® in Spain
-
Acorda Fourth Quarter/Year End 2022 Update: Webcast/Conference Call Scheduled for March 9, 2023
-
Acorda Therapeutics Receives Nasdaq Extension to Meet Minimum Bid Price Requirement
-
Acorda Therapeutics to Present at Sequire Biotechnology Conference
-
Acorda Therapeutics Announces New Agreement with Catalent for Long-Term Global Supply of INBRIJA®
-
Acorda Therapeutics Announces Revised Long-Term Financial Guidance
-
Acorda Therapeutics Receives Nasdaq Listing Determination Letter and Plans to Request a Hearing
-
Acorda Therapeutics Makes December 2022 $6.2 Million Interest Payment on Secured Debt in Cash
-
Acorda Therapeutics Announces Passage of Reverse Stock Split Proposal at its Special Meeting of Stockholders
-
Acorda Therapeutics Announces Adjournment of Special Meeting of Stockholders
-
Acorda Therapeutics Reports Third Quarter 2022 Financial Results
-
Acorda Therapeutics Provides Long-Term Business Plan and Financial Guidance
-
Acorda Third Quarter 2022 Update: Webcast/Conference Call Scheduled for November 1, 2022
-
Acorda Shareholders Invited to Virtual Q&A with CEO Ron Cohen, M.D.
-
ISS, Glass Lewis, and Egan-Jones Recommend that Acorda Stockholders Vote FOR the Proposal to Implement a Reverse Stock Split
-
Acorda Therapeutics Will Not Use Shares for December 2022 $6.2 Million Interest Payment on Secured Debt
-
Acorda Therapeutics Announces $16.5M Award and Royalty/Supply Relief in AMPYRA® Arbitration Case
-
Acorda Therapeutics Withdraws Proposal to Increase Authorized Shares from Special Meeting of Stockholders
-
Acorda Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
-
Acorda Therapeutics Enters into License Agreement with Asieris Pharmaceuticals
-
Acorda Therapeutics Announces Resignation of Chief Operating Officer
-
Acorda Therapeutics Reports Second Quarter 2022 Financial Results
-
Acorda Second Quarter 2022 Update: Webcast/Conference Call Scheduled for August 4, 2022
-
Esteve Launches INBRIJA® in Germany
-
Acorda Therapeutics Reports First Quarter 2022 Financial Results
Back to ACOR Stock Lookup